Clinical Trials on Uveal Melanoma in Germany

Total 326 results

University Hospital Tuebingen
University Hospital Dresden

Unknown

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) (BUMPER)

Malignant Melanoma | Metastases

Germany
IO Biotech
Merck Sharp & Dohme LLC; Syneos Health

Active, not recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Metastatic Melanoma | Unresectable Melanoma

Hungary, Spain, United Kingdom, Australia, France, Italy, United States, Denmark, Germany, Israel, Czechia, Belgium, Netherlands, Turkey, Poland, South Africa
Iovance Biotherapeutics, Inc.

Active, not recruiting

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)

Metastatic Melanoma

United States, Spain, Germany, United Kingdom, France, Hungary, Italy, Switzerland
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

Melanoma (Skin)

Italy, France, Spain, Switzerland, United Kingdom, Belgium, Australia, Norway, Poland, Finland, Netherlands, Germany, Israel, Denmark, Serbia, Estonia, Portugal, Russian Federation
Hoffmann-La Roche

Completed

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Malignant Melanoma

Italy, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
Maxim Pharmaceuticals
National Cancer Institute (NCI)

Unknown

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

Metastatic Cancer | Melanoma (Skin)

United States, Canada, Germany, United Kingdom
AstraZeneca

Completed

Study of CP-675,206 in Refractory Melanoma

Refractory Melanoma

United States, Spain, Canada, France, Italy, United Kingdom, Argentina, Australia, Germany
European Organisation for Research and Treatment...

Terminated

Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain

Metastatic Cancer | Melanoma (Skin)

France, Norway, Belgium, Netherlands, United Kingdom, Austria, Czech Republic, Germany, Italy, Portugal, Switzerland
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

Melanoma | Breast Cancer

United States, Germany
University Hospital, Essen

Active, not recruiting

Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma (NivoMela)

Malignant Melanoma Stage II

Germany
European Organisation for Research and Treatment...

Unknown

Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Spain, United Kingdom, Belgium, Australia, Poland, Germany, Netherlands, Slovenia, Italy, Switzerland, Israel, Bulgaria, Croatia, Czech Republic, Estonia, Portugal, Turkey
CancerVax Corporation

Unknown

Vaccine Therapy for Patients With Stage III Melanoma

Malignant Melanoma

United States, France, Australia, Canada, Germany, United Kingdom, Switzerland, Brazil, Ireland, Israel, Italy, Netherlands, New Zealand
CancerVax Corporation

Unknown

Vaccine Therapy for Patients With Stage IV Melanoma

Malignant Melanoma

United States, France, Australia, Canada, Germany, Switzerland, Brazil, Ireland, Israel, Italy, Netherlands, New Zealand, United Kingdom
Hoffmann-La Roche

Completed

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Malignant Melanoma

France, Germany, Italy, Sweden, United States, Australia, Canada, United Kingdom, Netherlands, Switzerland, New Zealand, Israel
Julius-Maximilians University

Unknown

Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer

Cervical Cancer | Pancreatic Cancer | Colon Cancer | Malignant Melanoma

Germany
European Organisation for Research and Treatment...

Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

Stage IV Melanoma | Unresectable Stage III Melanoma

France, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
Philogen S.p.A.

Recruiting

Neoadjuvant L19IL2/L19TNF- Pivotal Study (Pivotal)

Malignant Melanoma

Italy, France, Germany, Poland
Amgen

Completed

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (TVEC-325)

Unresected Stage IIIb to IVM1c Melanoma

France, Poland, Italy, Russian Federation, Netherlands, Spain, United States, Austria, Belgium, United Kingdom, Germany, Hungary, Greece
Technische Universität Dresden

Terminated

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases (RadioCoBRIM)

Brain Metastases | Malignant Melanoma Stage IV | BRAF V600 Mutation

Germany
Celgene
University of Arizona

Completed

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Malignant Melanoma

Canada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
Bristol-Myers Squibb

Completed

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Unresectable or Metastatic Melanoma

United States, Germany, Italy, United Kingdom, Canada, Denmark, Netherlands, Spain, Belgium, France, Switzerland, Israel, Austria, Brazil
Hoffmann-La Roche

Completed

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (coBRIM)

Malignant Melanoma

United States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
European Organisation for Research and Treatment...

Unknown

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Switzerland, Netherlands, Poland, Finland, Belgium, United Kingdom, Austria, Germany, Italy, Israel, Slovakia, Spain, Serbia, Portugal, Russian Federation, Bulgaria, Croatia, Turkey, Estonia, Sweden
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With Metastatic Melanoma

Malignant Melanoma

Canada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more
Array BioPharma

Terminated

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)

Melanoma

Canada, Spain, Australia, Switzerland, Germany, United States
Novartis Pharmaceuticals

Completed

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

Metastatic Melanoma and Merkel Cell Carcinoma

Germany, Switzerland
Immunocore Ltd

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

Advanced Melanoma

Spain, United States, Australia, Austria, Poland, France, Germany, Italy, Switzerland
Bristol-Myers Squibb

Completed

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)

Advanced Cutaneous Melanoma

Germany, Poland, Spain, Australia, France, Argentina, Ireland, Israel, Belgium, United States, Switzerland, United Kingdom, Greece, Austria, Canada
Bristol-Myers Squibb

Terminated

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Melanoma

France, United States, Italy, Germany, Austria
Merck Sharp & Dohme LLC

Terminated

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Advanced/Metastatic Melanoma

United States, Australia, Chile, France, Germany, Israel, Italy, Korea, Republic of, Norway, South Africa, Spain
University Hospital, Essen

Completed

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem)

Malignant Melanoma

Germany, France, Greece, Serbia
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Eisai Inc.

Completed

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Stage IV Melanoma | Unresectable Stage III

United States, United Kingdom, Australia, Germany
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Advanced BRAFV600 Wild-type Melanoma

United States, Korea, Republic of, Australia, Belgium, France, Russian Federation, Italy, Netherlands, Spain, United Kingdom, Brazil, Poland, Germany, Greece, Hungary
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Completed

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT)

Metastatic Melanoma

Italy, Germany, Spain, Greece, Austria, France, Poland, Sweden, Switzerland, United Kingdom
Idera Pharmaceuticals, Inc.
Bristol-Myers Squibb

Terminated

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Metastatic Melanoma

United States, Canada, Spain, United Kingdom, France, Australia, Germany, Italy, Netherlands, Sweden, Czechia
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
University of Wuerzburg
medac GmbH; Hiege-Stiftung gegen Hautkrebs; DCS Innovative Diagnostik Systeme

Unknown

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC (ChemoSensMM)

Melanoma

Germany
Bristol-Myers Squibb

Completed

PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

Melanoma

Italy, Netherlands, Russian Federation, Czechia, Hungary, Ireland, Norway, Spain, Switzerland, Austria, Germany, Denmark, France, Belgium, United Kingdom, United States
Vical

Completed

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

Metastatic Melanoma

United States, Belgium, Brazil, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Switzerland, Turkey
European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Unknown

Adjuvant PEG Intron in Ulcerated Melanoma

Ulcerated Melanomas

France, Denmark, Italy, Belgium, Spain, United Kingdom, Netherlands, Austria, Germany, Poland, Switzerland, Portugal
EuMelaReg gGmbH

Active, not recruiting

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients (Combi-EU)

Melanoma

Germany
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Malignant Melanoma

United States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
GlaxoSmithKline

Completed

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Melanoma

Australia, France, Germany, United States, Italy
Bristol-Myers Squibb

Withdrawn

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Melanoma | Urothelial Carcinoma

Germany, Spain
University Hospital Tuebingen

Terminated

Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

Metastatic Melanoma | Brain Metastases

Germany
Centocor, Inc.
Janssen-Cilag Farmaceutica, S.R.L.

Completed

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Melanoma

United States, United Kingdom, Germany
Bristol-Myers Squibb

Completed

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

High Risk Stage III Melanoma

Italy, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
Bristol-Myers Squibb

Completed

Phase II, 2nd Line Melanoma - RAND Monotherapy

Melanoma

France, Italy, United States, Germany, Canada, Denmark
Provectus Biopharmaceuticals, Inc.

Terminated

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Cutaneous Melanoma

United States, Mexico, France, Germany, Italy

Clinical Trials on Uveal Melanoma in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations